Chaperone-mediated autophagy protects against atherosclerosis
Open Access
- 19 July 2022
- journal article
- research article
- Published by Taylor & Francis in Autophagy
- Vol. 18 (10) , 2505-2507
Abstract
Atherosclerosis, the leading cause of cardiovascular death, is driven by hyperlipidemia, inflammation and aggravated by aging. As chaperone-mediated autophagy (CMA), a selective type of lysosomal degradation for intracellular proteins, diminishes with age and is inhibited by lipid excess, we studied if the decline in CMA could contribute to atherosclerosis pathogenesis. We found that CMA declines in human and murine vasculature with disease progression. Inhibition and reactivation of CMA using transgenic mouse models establishes a protective effect of CMA against atherogenesis. CMA upregulation ameliorates both systemic metabolic parameters, and vascular cell function. Our work suggests CMA reactivation could be a viable therapeutic strategy to prevent and reduce cardiovascular disease.Keywords
Funding Information
- American Heart Association (17POST33650088)
- Dutch Heart Foundation (Dr. Dekker fellowship 2016T060)
- Fondation Leducq (15CVD04)
- National Institutes of Health (AG021904, DK098408, AG031782)
- Dutch Research Council (VIDI 91718364, ASPASIA 015013064)
This publication has 1 reference indexed in Scilit:
- Protective role of chaperone-mediated autophagy against atherosclerosisProceedings of the National Academy of Sciences, 2022